Last reviewed · How we verify
anti-CGRP-mAbs — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
anti-CGRP-mAbs (anti-CGRP-mAbs) — Clínica de Intervención en Neurociencias. Monoclonal antibodies that bind to CGRP or its receptor, blocking the neuropeptide's role in migraine pain transmission and neurogenic inflammation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-CGRP-mAbs TARGET | anti-CGRP-mAbs | Clínica de Intervención en Neurociencias | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-CGRP-mAbs CI watch — RSS
- anti-CGRP-mAbs CI watch — Atom
- anti-CGRP-mAbs CI watch — JSON
- anti-CGRP-mAbs alone — RSS
Cite this brief
Drug Landscape (2026). anti-CGRP-mAbs — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cgrp-mabs. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing